Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12412399 | 0.80 | TSHR (0.40) | ALDH1A1KDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL5018871 | 0.78 | GALR3 (0.42) | ALDH1A1KDM4ECXCR5GALR3NR2F2 | |
| SCHEMBL4803010 | 0.77 | ALDH1A1 (0.45) | ALDH1A1KDM4ECXCR5GALR3NR2F2 | |
| SCHEMBL15372279 | 0.75 | KDM4E (0.56) | ALDH1A1KDM4ECXCR5GALR3NR2F2 | |
| SCHEMBL25799281 | 0.75 | PARP1 (0.37) | — | |
| SCHEMBL5024437 | 0.75 | GALR3 (0.47) | ALDH1A1KDM4ECXCR5GALR3NR2F2 | |
| SCHEMBL3873651 | 0.74 | ALDH1A1 (0.45) | ALDH1A1KDM4ECXCR5GALR3NR2F2 | |
| SCHEMBL1515558 | 0.74 | ALDH1A1 (0.45) | ALDH1A1KDM4ECXCR5GALR3NR2F2 | |
| SCHEMBL16807804 | 0.73 | PARP1 (0.41) | — | |
| SCHEMBL12844622 | 0.73 | GALR3 (0.44) | ALDH1A1KDM4ECXCR5GALR3NR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10202353-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9278975-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8946238-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | ALDH1A1 4211/4885KDM4E 44/4885CXCR5 484/4885 |
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | ALDH1A1 3052/4885KDM4E 1098/4885CXCR5 2640/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | ALDH1A1 3413/4885KDM4E 904/4885CXCR5 3968/4885 |
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | ALDH1A1 429/4885KDM4E 4459/4885CXCR5 898/4885 |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | ALDH1A1 1436/4885KDM4E 2068/4885CXCR5 211/4885 |
| US-10202353-B2 | Therapeutic compounds | RPL35, SARS1, HAVCR2 | ALDH1A1 424/4885KDM4E 4403/4885CXCR5 882/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | ALDH1A1 3317/4885KDM4E 100/4885CXCR5 1713/4885 |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | ALDH1A1 1436/4885KDM4E 2068/4885CXCR5 211/4885 |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | ALDH1A1 2824/4885KDM4E 1647/4885CXCR5 2572/4885 |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | ALDH1A1 1436/4885KDM4E 2068/4885CXCR5 211/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | ALDH1A1 1655/4885KDM4E 47/4885CXCR5 3688/4885 |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BAZ2A | ALDH1A1 3052/4885KDM4E 1098/4885CXCR5 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.